The aim of our study is to clarify the clinical e cacy between two different Bacillus Calmette-Guérin (BCG) strains, TICE strain (Oncotice) and Connaught strain (ImmuCyst) as rst line intravesical instillation therapy in patients with T1 high grade bladder urothelial cell carcinoma.
Methods:Between 2008 to 2022, patients with new diagnosed T1 high-grade bladder cancer received transurethral resection of bladder tumor (TURBT) and subsequent intravesical instillation therapy in Taichung Veterans General Hospital were retrospectively enrolled in this study. Patients were categorized into Connaught group and TICE group, based on the speci c BCG strain administered for treatment. Kaplan-Meier and Cox proportional hazards models analyzed BCG strain effects on recurrence, progression, and side effects.
Results
:Among 147 patients, 53 patients received Connaught strain and 94 patients received TICE strain. The median follow-up time was 89 months in the Connaught group and was 28 in the TICE group. The completion rate of BCG induction instillation was 92.45% in the Connaught group and 91.49% in the TICE group (p=1.00). The three-year recurrence-free survival rate was 71.7% in the Connaught group and 63.83% in the TICE group (p=0.33), while the three-year progression-free survival rate was 96.23% in the Connaught group and 89.36% in the TICE group (p=0.21). On Cox regression test, carcinoma in situ and ≥ 8 lesions were signi cant predictors for recurrence. Both of the two regimens exhibited no signi cant difference in terms of recurrence and progression. As for side effects, the frequency of cystitis (p = 0.011), UTI (p = 0.021), and hematuria (p = 0.042) were signi cant lower in the TICE group. The complication rates according to the Cleveland Clinic grading system showed no signi cant difference among the two groups (p=0.13).
Conclusions:In our study of T1 high-grade bladder urothelial cell carcinoma, both the Connaught strain and TICE strain BCG demonstrated comparable completion rates, 3-year recurrence-free survival rates, and 3-year progression-free survival rates. Adverse events were more frequent in the Connaught group, though the majority were of low grade. Given the global shortage of BCG, additional comparisons of the different strains are warranted to enable clinicians to validate their e cacy.escalates to 4.4%, positioning BC as the 6th most common cancer 1 . Within the Taiwanese context, the Ministry of Health and Welfare has reported BC as the 9th most frequently diagnosed cancer among men in 2017, with a substantial incidence rate of 14.57% corresponding to 1,707 cases per 100,000 male Taiwanese individuals 2 . Addressing this clinical challenge emerges as an imperative necessity.Recent investigation by Burger M. et al. showed that approximately 75% of newly diagnosed BC cases are non-muscle invasive tumor and have a notable rate of recurrence and progression even following localized therapeutic interventions 3 . According to the 2022 European Association of Urology (EAU) guideline on non-muscle-invasive bl...